Balaxi Pharmaceuticals (NSE:BALAXI) ROCE % : 13.62% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Balaxi Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Balaxi Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2024 was 13.62%.

Balaxi Pharmaceuticals ROCE % Historical Data

The historical data trend for Balaxi Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Balaxi Pharmaceuticals ROCE % Chart

Balaxi Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

56.25

95.65

61.35

38.31

1.89

Balaxi Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															37.02	23.71	15.18	11.00	13.62

Balaxi Pharmaceuticals ROCE % Calculation

Balaxi Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	36.924	/	( ( (2396.69 - 531.332)	+	(2583.432 - 541.973) )	/ 2 )
	=	36.924	/	( (1865.358	+	2041.459)	/ 2 )
	=	36.924	/	1953.4085
	=	1.89 %

Balaxi Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	297.86	/	( ( (2879.653 - 693.244)	+	(0 - 0) )	/ 1 )
	=	297.86	/	( ( 2186.409	+	0 )	/ 1 )
	=	297.86	/	2186.409
	=	13.62 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Balaxi Pharmaceuticals (NSE:BALAXI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Balaxi Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Balaxi Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Balaxi Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Balaxi Pharmaceuticals Ltd (NSE:BALAXI) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

Phase-III, Road No: 81, Jubilee Hills, Plot No.409, H,No: 8-2-293, MAPS Towers, 3rd Floor, Hyderabad, TG, IND, 500 096

Website

https://www.balaxipharma.in

Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. Geographically it earns key revenue from Guatemala.

Balaxi Pharmaceuticals Headlines

No Headlines